{"id":6500,"date":"2025-06-03T15:43:15","date_gmt":"2025-06-03T15:43:15","guid":{"rendered":"https:\/\/medicalaffairs.travere.com\/?post_type=episode&#038;p=6500"},"modified":"2025-10-15T12:19:22","modified_gmt":"2025-10-15T12:19:22","slug":"spartan-biomarkers","status":"publish","type":"episode","link":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/","title":{"rendered":"Insights from the SPARTAN Study"},"content":{"rendered":"\r\n\t<section style=\"padding-top:calc(150px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container has-background-image wp-elements-1e0efa5a75efc26a1084919928686d2a wp-block-grizzly-section-container has-text-color has-white-color has-background has-blue-background-color\">\r\n\t\t<img loading=\"lazy\" decoding=\"async\" width=\"1920\" height=\"897\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header.png\" class=\"hero-section-layer\" alt=\"Kidneys\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header.png 1920w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header-300x140.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header-1024x478.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header-768x359.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header-1536x718.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/03\/Header-290x135.webp 290w\" sizes=\"auto, (max-width: 1920px) 100vw, 1920px\" \/>\t\t<div class=\"container\">\r\n\t\t\t\n\n<h1 class=\"wp-block-heading has-text-align-center\" id=\"h-insights-from-the-spartan-study-with-drs-jonathan-barratt-and-shikha-wadhwani\" style=\"margin-bottom:calc(45px * var(--scale))\">Insights from the SPARTAN Study with Drs. Jonathan Barratt and Shikha Wadhwani<\/h1>\n\n\n<div class=\"podcast\">\n\t\t\t\t<iframe src=\"https:\/\/share.transistor.fm\/e\/a62589fb?color=06304B&#038;background=ffffff\" title=\"Podcast Player\" frameborder=\"0\" allowfullscreen loading=\"lazy\"><\/iframe>\n\t<\/div>\n\t\t<\/div>\r\n\t<\/section>\r\n\t\t\t<svg width=\"100%\" viewBox=\"0 0 1440 95\" fill=\"none\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"wave\">\r\n\t\t\t<path d=\"M0 94.883h1440v-55C971.349 142.422 479-88.172 0 39.828v55.055Z\" fill=\"#fff\"\/>\r\n\t\t<\/svg>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:calc(30px * var(--scale));padding-left:0px;\" class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\" style=\"margin-bottom:calc(45px * var(--scale))\">\n<p class=\"has-text-align-center\">Dr. Jonathan Barratt, PhD, FRCP is the Professor of Renal Medicine at the University of Leicester, where he leads the IgA Nephropathy Research Group. He is internationally recognized for his leadership in translational and clinical research in glomerular diseases, particularly IgA nephropathy. Dr. Barratt directs UK\u2019s Rare Disease Group for the UK National Registry of Rare Kidney Diseases (RaDaR).<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\">Dr. Shikha Wadhwani, MD, MS, FASN is an Associate Professor of Medicine in the Division of Nephrology and Vice Chair of Clinical Research in the Department of Medicine at University of Texas Medical Branch (UTMB). She is also the inaugural Associate Research Officer for clinical research, overseeing clinical trials across all 5 schools at UTMB. She is the founding member of the International Society of Glomerular Disease (ISGD) and is steering a global effort aimed at supporting the growth and success of physician-trialists. In her spare time, Dr. Wadhwani co-hosts a podcast called<em> Kidney Compass: Navigating Clinical Trials.<\/em><\/p>\n\n\n\n<div style=\"height:60px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\">In this episode, Drs. Jonathan Barratt and Shikha Wadhwani discuss findings from the <a href=\"https:\/\/clleancode.top\/travere-redesign\/posters\/spartan-urinary-biomarker-interim-analysis\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"text-decoration-underline\">SPARTAN Study<\/span><\/a>, a Phase 2, open-label, single-arm trial evaluating sparsentan in 12 treatment-na\u00efve patients with IgA nephropathy. The conversation explores the trial design, including assessments of proteinuria reduction and urinary biomarkers to better understand the sparsentan mechanism of action.<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\">Results from SPARTAN demonstrated a 69% median reduction in proteinuria at 24 weeks, alongside biomarker trends consistent with decreased glomerular inflammation.<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\">Dr. Barratt notes that no new safety signals emerged, with hypotension observed at a rate consistent with prior studies and no adverse hepatic events reported.<\/p>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center\" style=\"margin-bottom:calc(60px * var(--scale))\">Together, the experts reflect on how these data support the biological plausibility of the anti-inflammatory properties of sparsentan and how they may inform the development of biomarker-guided strategies in IgA nephropathy, including ongoing evaluation of sparsentan in the <a href=\"https:\/\/clleancode.top\/travere-redesign\/publications\/protect-2-year-results-sparsentan-vs-irbesartan-iga-nephropathy\/\" target=\"_blank\" rel=\"noreferrer noopener\"><span class=\"text-decoration-underline\">PROTECT trial<\/span><\/a>.<\/p>\n<\/div>\n\n\n<div class=\"platforms\">\n\t\t\t\t<p>Also find us on:\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/open.spotify.com\/episode\/4xUkn09bfjVqiGEdUHrY7M?si=cf294235d2504368\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"platform-links--border\">\n\t\t\t\t\t\t<span class=\"icon2-spotify\" aria-hidden=\"true\"><\/span> Spotify\n\t\t\t\t\t<\/a>\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/player.vimeo.com\/video\/1115153147\" target=\"_blank\" rel=\"noreferrer noopener\" class=\"platform-links--border\">\n\t\t\t\t\t\t<span class=\"icon2-vimeo\" aria-hidden=\"true\"><\/span> Vimeo\n\t\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/p>\n\t<\/div>\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(30px * var(--scale));padding-right:0px;padding-bottom:0px;padding-left:0px;\" class=\"section-container section-video wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-content-justification-center is-layout-constrained wp-container-core-group-is-layout-10864c57 wp-block-group-is-layout-constrained\">\n<div class=\"podcast-video\">\n\t<a href=\"#\" class=\"podcast-video--img\" style=\"background-image: url('https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/MCE1359-Travere-RKD-Newsletter-Banner-V00-01-20250829.webp');\" aria-label=\"Play video\">\n\t\t<div class=\"podcast-video--inner\">\n\t\t\t<p class=\"has-heading-4-font-size\">Watch the video to see the accompanying slides and visuals<\/p>\n\t\t\t<span class=\"icon2-play\"><\/span>\n\t\t<\/div>\n\t<\/a>\n\t<div class=\"podcast-video--vimeo\"><\/div>\n<\/div>\n\n<script src=\"https:\/\/player.vimeo.com\/api\/player.js\"><\/script>\n<script>\n\tdocument.addEventListener(\"DOMContentLoaded\", function() {\n\t\tconst imgLink = document.querySelector(\".podcast-video--img\");\n\t\tconst vimeoDiv = document.querySelector(\".podcast-video--vimeo\");\n\t\tlet iframeExists = false;\n\t\tlet player;\n\n\t\timgLink.addEventListener(\"click\", function(event) {\n\t\t\tevent.preventDefault();\n\n\t\t\tif (!iframeExists) {\n\t\t\t\tconst iframe = document.createElement(\"iframe\");\n\t\t\t\tiframe.src = \"https:\/\/player.vimeo.com\/video\/1115153147\";\n\t\t\t\tiframe.frameBorder = \"0\";\n\t\t\t\tiframe.allow = \"autoplay; fullscreen\";\n\t\t\t\tiframe.loading = \"lazy\";\n\t\t\t\tiframe.setAttribute(\"allowfullscreen\", \"\");\n\n\t\t\t\tvimeoDiv.appendChild(iframe);\n\t\t\t\tplayer = new Vimeo.Player(iframe);\n\t\t\t\tplayer.play();\n\t\t\t\tiframeExists = true;\n\t\t\t}\n\n\t\t\tvimeoDiv.style.display = \"block\";\n\t\t\timgLink.style.display = \"none\";\n\t\t});\n\n\t\tvimeoDiv.addEventListener(\"click\", function() {\n\t\t\tconst iframe = vimeoDiv.querySelector(\"iframe\");\n\t\t\tiframe.contentWindow.postMessage('{\"method\":\"play\"}', 'https:\/\/player.vimeo.com\/video\/1115153147');\n\t\t});\n\t});\n<\/script>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section style=\"padding-top:calc(40px * var(--scale));padding-right:0px;padding-bottom:calc(60px * var(--scale));padding-left:0px; background-color:#f8f8f8;\" class=\"section-container wp-block-grizzly-section-container has-background\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\">\n<h2 class=\"wp-block-heading has-heading-3-font-size has-text-color has-link-color wp-elements-e4f52c3ea4e9e98cf562e94e619e7d49\" id=\"h-episode-summary\" style=\"color:#00b49e;margin-bottom:calc(60px * var(--scale))\"><strong>Episode Summary<\/strong><\/h2>\n\n\n\t\t<div class=\"summary-block\">\n\t\t\t<p>\u201cWhat we have is treatment with sparsentan from time of diagnosis, and that\u2019s really powerful because it allows us to look at what sparsentan delivers in terms of kidney function protection in na\u00efve patients, but also what it delivers in terms of biomarker changes.\u201d 02:18<\/p> \n\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t\t<div class=\"summary-block\">\n\t\t\t<p>\u201cIt gives us a possibility of interrelating the things we use in clinical practice with novel biomarkers that we can then validate in the PROTECT trial and potentially use in future clinical practice. That is the aspiration for the study.\u201d 15:54<\/p> \n\t\t<\/div>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\t\t<div class=\"summary-block\">\n\t\t\t<p>\u201cThe more we understand about what we can do to halt disease progression in IgAN, hopefully the better we can do for our patients. These types of mechanistic studies will move us towards new biomarkers so we can follow patients better, intervene at a more appropriate time, and hopefully change the trajectory of the disease.\u201d 22:48<\/p> \n\t\t<\/div>\n\n\n<div class=\"wp-block-list-wrapper\">\n<ul class=\"wp-block-list\">\n<li>SPARTAN demonstrated a robust mean reduction in proteinuria (~69%) in treatment-na\u00efve patients with IgA nephropathy after 24 weeks of sparsentan therapy<\/li>\n\n\n\n<li>Biomarker analysis revealed reductions in markers of macrophage activation, complement activity, and inflammatory cytokines, supporting the hypothesis of a potential anti-inflammatory effect<\/li>\n\n\n\n<li>No new safety signals were observed; hypotension rates were consistent with earlier trials, and no clinically significant changes in hepatic function were reported<\/li>\n\n\n\n<li>These findings contribute to our mechanistic understanding of sparsentan and provide a framework for future investigation of biomarkers from samples from larger studies such as PROTECT<\/li>\n<\/ul>\n<\/div>\n\n\n<div style=\"height:38px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong>Disclaimer:<\/strong> Guest speakers of the Rare Kidney Disease Show may be paid consultants of Travere Therapeutics. This podcast episode was recorded on July 25, 2025. Please always consult updated sources for the latest information, as information discussed may have changed since the recording date.<\/p>\n\n\n\n<p class=\"smaller-text\" style=\"margin-top:calc(60px * var(--scale))\">MA-SP-25-0119<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t\n\n\r\n\t<section class=\"section-container wp-block-grizzly-section-container\">\r\n\t\t\t\t<div class=\"container\">\r\n\t\t\t\n\n<div class=\"wp-block-group is-layout-constrained wp-container-core-group-is-layout-09ab29e6 wp-block-group-is-layout-constrained\" style=\"margin-bottom:calc(45px * var(--scale));padding-top:calc(60px * var(--scale));padding-bottom:calc(60px * var(--scale))\">\n<div id=\"episodes\" class=\"episodes\" style=\"\">\n\t<div class=\"episodes-title\">\n\t\t<p class=\"has-heading-3-font-size\">Episodes<\/p>\n\t\t\t<\/div>\n\n\t\t\t\t<div class=\"episodes-list\">\n\t\t\t\t\t<article class=\"m-card m-card--podcast \">\n\t\t<div class=\"m-card__top\">\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/\"  aria-label=\"View episode: Insights from the SPARTAN Study\">\n\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"2560\" height=\"2560\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp\" class=\"a-img h-object-position-top-center\" alt=\"Insights from the SPARTAN Study\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-300x300.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-1024x1024.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-150x150.webp 150w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-768x768.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-1536x1536.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-2048x2048.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-290x290.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon2-apple-podcast\"><\/i> Podcast\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">IgAN<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tInsights from the SPARTAN Study\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">Ft. Drs. Jonathan Barratt and Shikha Wadhwani<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Listen to episode: Insights from the SPARTAN Study\">\n\t\t\t\t\t\t<span>Listen to episode<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t<article class=\"m-card m-card--podcast \">\n\t\t<div class=\"m-card__top\">\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/fsgs-podocytopathy\/\"  aria-label=\"View episode: From Podocyte to Patient\">\n\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"2560\" height=\"2560\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-scaled.webp\" class=\"a-img h-object-position-top-center\" alt=\"From Podocyte to Patient\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-300x300.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-1024x1024.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-150x150.webp 150w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-768x768.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-1536x1536.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-2048x2048.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/06\/Ep-7-graphic-290x290.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon2-apple-podcast\"><\/i> Podcast\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tFrom Podocyte to Patient\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">The Pathophysiology of FSGS<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/fsgs-podocytopathy\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Listen to episode: From Podocyte to Patient\">\n\t\t\t\t\t\t<span>Listen to episode<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t<article class=\"m-card m-card--podcast \">\n\t\t<div class=\"m-card__top\">\n\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/fsgs-introduction\/\"  aria-label=\"View episode: Introduction to FSGS\">\n\t\t\t\t\t\t\t\t\t<img decoding=\"async\" width=\"2560\" height=\"2560\" src=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-scaled.webp\" class=\"a-img h-object-position-top-center\" alt=\"Introduction to FSGS\" loading=\"lazy\" srcset=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-scaled.webp 2560w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-300x300.webp 300w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-1024x1024.webp 1024w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-150x150.webp 150w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-768x768.webp 768w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-1536x1536.webp 1536w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-2048x2048.webp 2048w, https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/01\/Ep-6-graphic-290x290.webp 290w\" sizes=\"auto, (max-width: 2560px) 100vw, 2560px\" \/>\t\t\t\t\t\t\t<\/a>\n\t\t\t<div class=\"m-card__info\">\n\t\t\t\t<div class=\"m-tags\">\n\t\t\t\t\t<span class=\"a-tag h-blue\">\n\t\t\t\t\t\t<i class=\"icon2-apple-podcast\"><\/i> Podcast\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<span class=\"a-tag h-blue\">Nephrology<\/span><span class=\"a-tag h-blue\">FSGS<\/span>\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t<\/div>\n\t\t<div class=\"m-card__bottom m-card--padding\">\n\t\t\t<div class=\"m-card__text\">\n\t\t\t\t<p class=\"a-heading a-heading--h4 h-ultra-dark-blue h-text-ellipsis h-w-medium\">\n\t\t\t\t\tIntroduction to FSGS\t\t\t\t<\/p>\n\t\t\t\t\t\t\t\t<p class=\"a-text a-text--m h-ultra-dark-blue\">Ft. Dr. Howard Trachtman<\/p>\n\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<a href=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/fsgs-introduction\/\" class=\"a-btn a-btn--secondary--blue\"  aria-label=\"Listen to episode: Introduction to FSGS\">\n\t\t\t\t\t\t<span>Listen to episode<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t\t<\/div>\n\t<\/article>\n\t\t\t<\/div>\n\t\t\t\t<\/div>\n\n\n<p class=\"has-text-align-right smaller-text\" style=\"margin-top:calc(60px * var(--scale));margin-bottom:calc(180px * var(--scale))\">MA-SP-25-0128 | September 2025<\/p>\n<\/div>\n\n\t\t<\/div>\r\n\t<\/section>\r\n\t","protected":false},"featured_media":6505,"parent":5968,"menu_order":0,"template":"","meta":{"inline_featured_image":false,"header_bg_color":"transparent","header_fixed":true,"post_description":"","post_download_link":""},"product":[78],"therapeutic_area":[97],"disease_area":[174],"study_registry":[188],"study_type":[176],"resource_type":[196],"class_list":["post-6500","episode","type-episode","status-publish","has-post-thumbnail","hentry","product-spa","therapeutic_area-neph","disease_area-igan","study_registry-spartan","study_type-clinical","resource_type-podcast"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.9 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SPARTAN | RKD Show | Travere Global Medical Affairs<\/title>\n<meta name=\"description\" content=\"Learn more about the urinary biomarker findings in the Phase 2 SPARTAN study as presented at the recent 2025 ISGD Podocyte meeting.\" \/>\n<meta name=\"robots\" content=\"noindex, nofollow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insights from the SPARTAN Study\" \/>\n<meta property=\"og:description\" content=\"Learn more about the urinary biomarker findings in the Phase 2 SPARTAN study as presented at the recent 2025 ISGD Podocyte meeting.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/\" \/>\n<meta property=\"og:site_name\" content=\"Travere Medical Affairs\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/TravereRare\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T12:19:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"2560\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@TravereRare\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/\",\"name\":\"SPARTAN | RKD Show | Travere Global Medical Affairs\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/RKD-Show-SPARTAN-Artwork-scaled.webp\",\"datePublished\":\"2025-06-03T15:43:15+00:00\",\"dateModified\":\"2025-10-15T12:19:22+00:00\",\"description\":\"Learn more about the urinary biomarker findings in the Phase 2 SPARTAN study as presented at the recent 2025 ISGD Podocyte meeting.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/RKD-Show-SPARTAN-Artwork-scaled.webp\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/RKD-Show-SPARTAN-Artwork-scaled.webp\",\"width\":2560,\"height\":2560},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/spartan-biomarkers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Rare Kidney Disease\",\"item\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/podcasts\\\/rare-kidney-disease-show\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Insights from the SPARTAN Study with Drs. Jonathan Barratt and Shikha Wadhwani\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#website\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"name\":\"Travere Medical Affairs\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#organization\",\"name\":\"Travere Therapeutics\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"contentUrl\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/wp-content\\\/uploads\\\/2024\\\/01\\\/Travere-Global-Medical-Affairs-Logo.png\",\"width\":420,\"height\":152,\"caption\":\"Travere Therapeutics\"},\"image\":{\"@id\":\"https:\\\/\\\/clleancode.top\\\/travere-redesign\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/TravereRare\\\/\",\"https:\\\/\\\/x.com\\\/TravereRare\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SPARTAN | RKD Show | Travere Global Medical Affairs","description":"Learn more about the urinary biomarker findings in the Phase 2 SPARTAN study as presented at the recent 2025 ISGD Podocyte meeting.","robots":{"index":"noindex","follow":"nofollow"},"og_locale":"en_US","og_type":"article","og_title":"Insights from the SPARTAN Study","og_description":"Learn more about the urinary biomarker findings in the Phase 2 SPARTAN study as presented at the recent 2025 ISGD Podocyte meeting.","og_url":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/","og_site_name":"Travere Medical Affairs","article_publisher":"https:\/\/www.facebook.com\/TravereRare\/","article_modified_time":"2025-10-15T12:19:22+00:00","og_image":[{"width":2560,"height":2560,"url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@TravereRare","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":["WebPage","ItemPage"],"@id":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/","url":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/","name":"SPARTAN | RKD Show | Travere Global Medical Affairs","isPartOf":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#website"},"primaryImageOfPage":{"@id":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/#primaryimage"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/#primaryimage"},"thumbnailUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp","datePublished":"2025-06-03T15:43:15+00:00","dateModified":"2025-10-15T12:19:22+00:00","description":"Learn more about the urinary biomarker findings in the Phase 2 SPARTAN study as presented at the recent 2025 ISGD Podocyte meeting.","breadcrumb":{"@id":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/#primaryimage","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2025\/09\/RKD-Show-SPARTAN-Artwork-scaled.webp","width":2560,"height":2560},{"@type":"BreadcrumbList","@id":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/spartan-biomarkers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/clleancode.top\/travere-redesign\/"},{"@type":"ListItem","position":2,"name":"Rare Kidney Disease","item":"https:\/\/clleancode.top\/travere-redesign\/podcasts\/rare-kidney-disease-show\/"},{"@type":"ListItem","position":3,"name":"Insights from the SPARTAN Study with Drs. Jonathan Barratt and Shikha Wadhwani"}]},{"@type":"WebSite","@id":"https:\/\/clleancode.top\/travere-redesign\/#website","url":"https:\/\/clleancode.top\/travere-redesign\/","name":"Travere Medical Affairs","description":"","publisher":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/clleancode.top\/travere-redesign\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/clleancode.top\/travere-redesign\/#organization","name":"Travere Therapeutics","url":"https:\/\/clleancode.top\/travere-redesign\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/","url":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","contentUrl":"https:\/\/clleancode.top\/travere-redesign\/wp-content\/uploads\/2024\/01\/Travere-Global-Medical-Affairs-Logo.png","width":420,"height":152,"caption":"Travere Therapeutics"},"image":{"@id":"https:\/\/clleancode.top\/travere-redesign\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/TravereRare\/","https:\/\/x.com\/TravereRare"]}]}},"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-04-24 10:00:29","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"podcast","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/episode\/6500","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/episode"}],"about":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/types\/episode"}],"up":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/episode\/5968"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media\/6505"}],"wp:attachment":[{"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/media?parent=6500"}],"wp:term":[{"taxonomy":"product","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/product?post=6500"},{"taxonomy":"therapeutic_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/therapeutic_area?post=6500"},{"taxonomy":"disease_area","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/disease_area?post=6500"},{"taxonomy":"study_registry","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_registry?post=6500"},{"taxonomy":"study_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/study_type?post=6500"},{"taxonomy":"resource_type","embeddable":true,"href":"https:\/\/clleancode.top\/travere-redesign\/wp-json\/wp\/v2\/resource_type?post=6500"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}